0001415889-24-001828.txt : 20240125
0001415889-24-001828.hdr.sgml : 20240125
20240125200025
ACCESSION NUMBER: 0001415889-24-001828
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240123
FILED AS OF DATE: 20240125
DATE AS OF CHANGE: 20240125
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Leheny A. Rachel
CENTRAL INDEX KEY: 0001484729
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39538
FILM NUMBER: 24563788
MAIL ADDRESS:
STREET 1: C/O ANTHERA PHARMACEUTICALS, INC.
STREET 2: 25801 INDUSTRIAL BOULEVARD, SUITE B
CITY: HAYWARD
STATE: CA
ZIP: 94545
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CalciMedica, Inc.
CENTRAL INDEX KEY: 0001534133
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 452120079
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 505 COAST BOULEVARD SOUTH
STREET 2: SUITE 307
CITY: LA JOLLA
STATE: CA
ZIP: 92037
BUSINESS PHONE: 858-952-5500
MAIL ADDRESS:
STREET 1: 505 COAST BOULEVARD SOUTH
STREET 2: SUITE 307
CITY: LA JOLLA
STATE: CA
ZIP: 92037
FORMER COMPANY:
FORMER CONFORMED NAME: CalciMedica, Inc. /DE/
DATE OF NAME CHANGE: 20230322
FORMER COMPANY:
FORMER CONFORMED NAME: GRAYBUG VISION, INC.
DATE OF NAME CHANGE: 20170717
FORMER COMPANY:
FORMER CONFORMED NAME: GRAYBUG, Inc.
DATE OF NAME CHANGE: 20150303
4
1
form4-01252024_080101.xml
X0508
4
2024-01-23
0001534133
CalciMedica, Inc.
CALC
0001484729
Leheny A. Rachel
C/O CALCIMEDICA, INC.
505 COAST BLVD. S. #307
LA JOLLA
CA
92037
true
true
true
false
CHIEF EXECUTIVE OFFICER
0
Common Stock
2024-01-23
4
A
0
91086
4.2665
A
109926
D
Common Stock
1000
I
By Spouse
Common Stock
356989
I
By Valence Investments SPV IV, LLC
Common Stock
66228
I
By Valence Investments SPV V, LLC
Common Stock
316109
I
By Valence Investments SPV VI, LLC
Warrant
5.36
2024-01-23
4
A
0
45543
0.125
A
2024-01-23
2024-12-31
Common Stock
45543
45543
D
Warrant
7.15
2024-01-23
4
A
0
45543
0.125
A
2024-01-23
2026-12-31
Common Stock
45543
45543
D
The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.
The Reporting Person, a co-founder and managing director of Valence Investments SPV IV, LLC ("Valence IV"), Valence Investments SPV V, LLC ("Valence V") and Valence Investments SPV VI, LLC (Valence VI), may be deemed to beneficially own the securities held by Valence IV, Valence V and Valence VI (the "Valence Securities"). The Reporting Person disclaims beneficial ownership of the Valence Securities except to the extent of her pecuniary interest therein.
The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter.
The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter.
/s/ John Dunn, Attorney-in-Fact
2024-01-25